Detrimental Effect of Fungal 60-kDa Heat Shock Protein on Experimental Paracoccidioides brasiliensis Infection

Fabrício Freitas Fernandes, Leandro Licursi de Oliveira, Taise Natali Landgraf, Gabriela Peron, Marcelo Vieira Costa, Arlete A. M. Coelho-Castelo, Vânia L. D. Bonato, Maria-Cristina Roque-Barreira, Ademilson Panunto-Castelo

1 Department of Cellular and Molecular Biology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, SP, Brazil, 2 Department of General Biology, Federal University of Viçosa, Viçosa, MG, Brazil, 3 Department of Biochemistry and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil, 4 Department of Structural and Functional Biology, Institute of Biology, State University of Campinas, Campinas, SP, Brazil, 5 Department of Biology, Ribeirão Preto Faculty of Philosophy, Sciences and Letters, University of São Paulo, Ribeirão Preto, SP, Brazil

* apcastelo@usp.br

Abstract

The genus Paracoccidioides comprises species of dimorphic fungi that cause paracoccidioidomycosis (PCM), a systemic disease prevalent in Latin America. Here, we investigated whether administration of native 60-kDa heat shock protein of P. brasiliensis (nPbHsp60) or its recombinant counterpart (rPbHsp60) affected the course of experimental PCM. Mice were subcutaneously injected with nPbHsp60 or rPbHsp60 emulsified in complete Freund Adjuvant (CFA) at three weeks after intravenous injection of P. brasiliensis yeasts. Infected control mice were injected with CFA or isotonic saline solution alone. Thirty days after the nPbHsp60 or rPbHsp60 administration, mice showed remarkably increased fungal load, tissue inflammation, and granulomas in the lungs, liver, and spleen compared with control mice. Further, rPbHsp60 treatment (i) decreased the known protective effect of CFA against PCM and (ii) increased the concentrations of IL-17, TNF-α, IL-12, IFN-γ, IL-4, IL-10, and TGF-β in the lungs. Together, our results indicated that PbHsp60 induced a harmful immune response, exacerbated inflammation, and promoted fungal dissemination. Therefore, we propose that PbHsp60 contributes to the fungal pathogenesis.

Introduction

The genus Paracoccidioides includes species of dimorphic fungi that cause paracoccidioidomycosis (PCM), a granulomatous systemic mycosis prevalent in Latin America [1–3]. Paracoccidioides fungi are thermally dimorphic and grow as hypha at the environmental temperature and as yeast at 35°C-37°C. Fungal morphologic transition is essential for establishing an infection because infective conidia or mycelial fragments are inhaled and converted to pathogenic yeast forms in the host lungs [4, 5]. Prevalence of PCM is higher in men in rural areas who are
involved in activities related to the management of contaminated soil and plants [6]. *P. brasiliensis* may also affect immunocompromised individuals as an occasional opportunistic infection that results in severe clinical manifestations and a high mortality rate [7]. Fungal invasion of host tissues induces inflammation characterized by macrophage activation and granuloma formation, which controls the dissemination of *Paracoccidioides* yeasts to other organs [8].

Clinical manifestations of *Paracoccidioides* infection may be directly associated with fungal factors, such as virulence and pathogenicity [9], or are related to host factors, such as genetic susceptibility and immune competence [10, 11]. However, fungal and host factors are intricately connected to each other because disease outcome depends on the interaction of fungal components with receptors on host phagocytic cells [12]. For this reason, strains of *P. brasiliensis*, which is the most studied species of the genus *Paracoccidioides*, have variable degrees of virulence and, consequently, can induce different host responses [13]. Interestingly, Bonfim et al. [13] described that less virulent *P. brasiliensis* strain is preferably recognized by receptors dectin-1 and Toll-like receptor (TLR) 2 present on innate immune cells and induce the production of balanced amounts of TNF-α and IL-10. On the other hand, most virulent *P. brasiliensis* strain promotes the production of TNF-α but not IL-10. These observations suggest that less virulent *P. brasiliensis* strains induce a more controlled response because IL-10, an anti-inflammatory cytokine, prevents host tissue injury that may result from TNF-α activity [13].

Several studies have identified and characterized components of *Paracoccidioides* fungi involved in their infection and pathogenicity to better understand their biology and interactions with host cells and to identify potential vaccine targets. Lipids, polysaccharides, and proteins were already mentioned as able to increase fungal pathogenicity [14, 15]. Studies with plasmid DNA cloned with the gene of heat shock protein (Hsp) of 65-kDa from *Mycobacterium leprae* [16] and with the gene encoding the P10 peptide from gp43 [17] have shown therapeutic effects in experimental PCM. *P. brasiliensis* proteins are the most studied because of their high immunogenicity. For example, gp43, which is the most studied component of *P. brasiliensis* yeasts, has significant potential for application in vaccine development or immunotherapy against PCM [15]. Also, a 27-kDa component of *P. brasiliensis* is under investigation for its use in the prophylaxis and treatment of PCM [18]. The rPb27 and rPb40, in addition to fluconazole chemotherapy, showed an additive protective effect [19, 20]. Moreover, the *P. brasiliensis* lectin, paracoccin, by interacting with TLR2 N-glycans on host cells, establishes protective responses against PCM [21].

To identify *P. brasiliensis* antigens that contributed to its pathogenicity and that could serve as potential vaccines or therapeutic targets, we examined *P. brasiliensis* components that bind to immobilized fetuin. Interestingly, the major component of the fetuin-bound fraction was identified as the heat shock protein of *P. brasiliensis* and the preparation was designed as nPbHsp60. Its administration or the administration of its recombinant counterpart (rPbHsp60) induced detrimental effects in *P. brasiliensis*-infected mice. Therefore, we propose that PbHsp60 contributes to the fungal pathogenesis.

**Materials and Methods**

**Mice and Ethics Statement**

This study was conducted in accordance with the ethical principles of animal research adopted by the Brazilian Society of Laboratory Animal Science and was approved by the Ethics Committee on Animal Use of the Ribeirão Preto Medical School, USP (protocol: 146/2007). Male BALB/c mice between 6–8 weeks of age and weighing 20–25 g (n = 5/group) were obtained from the Animal Facility of Ribeirão Preto Campus and were maintained at the Animal Facility of Ribeirão Preto School of Medicine, University of São Paulo (USP). They were acclimated to
the facility for one week prior to initiating the experiment, housed in individually ventilated
cages, light-tight cabinets (Alesco, Capivari, Brazil), maintained at 20–22°C, a 12 h light-dark
cycle, and with access to chow and water ad libitum. All cages were cleaned twice a week and
bedded with autoclaved soft wood shavings.

Fungal Isolate

Yeast cells of a highly virulent \textit{P. brasiliensis} strain (Pb18) were cultured on YPD broth (1% yeast extract, 2% peptone, and 2% dextrose) and were incubated at 36°C for 7 days. Virulence and viability of the yeast cells were maintained as described previously \cite{22, 23}. Briefly, the virulence was maintained by constant mice infections and recovery of Pb18 strain. The viability was performed by the fluorescein diacetate-ethidium bromide treatment Only suspensions containing >90% viable cells were used for infecting mice.

Antigen Preparation

Cultured yeast cells were harvested by centrifugation at 7,000 × g at 4°C for 10 minutes, washed with 10 mM phosphate-buffered saline (PBS), pH 7.2, and disrupted by sonication on ice (five cycles of 1 minute each) at 200 W (Unique UltraSonic Mixing, mod. DES 500, 4 mm probe; Unique Group, Indaiatuba, Brazil), followed by centrifugation at 7,000 × g at 4°C for 10 minutes. Supernatant containing \textit{P. brasiliensis} soluble antigens (PbAgs) was filtered through a 0.22-μm filter (Millipore, Billerica, USA). Approximately 5 mg PbAgs were resolved by performing chromatography with a 5-mL fetuin—agarose column (Sigma Chemical Co., St. Louis, USA) that was previously equilibrated with 20 mM sodium phosphate buffer (pH 7.4). After washing with 10 column volumes (cv) of the equilibrating buffer, the column was sequentially eluted using 5 cv of 0.4 M D-glucose, D-mannose, D-galactose, or α-lactose in PBS or with 1 M NaCl in PBS. The eluted fractions were dialyzed against water by using centrifugal filtration devices with a molecular weight cut-off of 10,000 kDa (Millipore). Concentration of proteins eluted with 1 M NaCl was determined using a BCA kit (Pierce Chemical Co., Rockford, USA).

Electrophoresis and Protein Identification

Eluted protein and rPbHsp60 (~5 μg) were resuspended in 5× loading buffer (500 mM Tris-HCl [pH 6.5], 2.5% SDS, 10% glycerol, 2.5% β-mercaptoethanol, and 0.1% bromophenol blue) and were heated at 100°C for 3 minutes. Next, the preparations were resolved by performing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 12.5% by using Mini-Protean Tetra System (Bio-Rad Laboratories, Richmond, USA). The gels were stained with Coomassie brilliant blue G250 (USB Corporation, Cleveland, USA). Proteins with known molecular masses were used as standards (LMW-SDS Marker Kit; GE Healthcare UK Ltd, Buckinghamshire, England). A semi-quantitative analysis of the relative amount of 68-kDa protein band was carried out by converting the density of protein bands in the gel picture using the ImageJ 1.37v software (National Institutes of Health, Bethesda, USA) as the percent of the total gel density. Next, 60-kDa bands from column-eluted fraction and rPbHsp60 were excised from the gel, were digested \textit{in situ} with trypsin. Peptides were extracted from gel and dried in SpeedVac, resuspended in 50 μl 1% formic acid, centrifuged and transferred to HPLC vial. Ten μl sample was typically analyzed on the system. All mass spectrometry analyses were performed on an Agilent 6520 Q-TOF mass spectrometer equipped with an Agilent 1200 series liquid chromatograph and an Agilent Chip Cube LC-MS interface (1D nLC-MS-MS) at the FingerPrint Proteomics and Mass Spectrometry Facility, College of Life Sciences, University of Dundee. Mascot (version 2.3; Matrix, United Kingdom) analysis was performed to identify peptides and to search for proteins in the NCBI nonredundant (nr) database. The identified
peptides were searched against NCBI nr E. coli database to find possible bacterial protein contaminants in the sample.

Cloning of *P. brasiliensis* cDNA Encoding PbHsp60

Total RNA was extracted from *P. brasiliensis* yeast culture by using Trizol (Life Technologies, Carlsbad, USA), according to the manufacturer’s protocol. Reverse transcription-PCR (RT-PCR) was performed using oligo-dT primer (Life Technology) and SuperScript II Reverse Transcriptase (Life Technologies) for synthesizing cDNA. To amplify the cDNA region encoding PbHsp60 were used the oligonucleotide primers 5′-CGAATTCATGATGCAGCGAGCTTTTACTTCCT-3′ (sense) and 5′-CTCGAGGAACATACCCCCGCCCATAC-3′ (antisense) and high-fidelity *Taq* polymerase (Life Technologies). The amplified fragment was cloned into pGEM-T vector (Promega, Madison, USA) and was sequenced at the Center for Human Genome Studies, Institute of Biosciences, USP. Next, the fragment was removed from the pGEM-T vector by using EcoRI and XhoI and was subcloned into pET28a vector (Novagen, San Diego, USA).

Expression and Purification of rPbHsp60 in *Escherichia coli*

*E. coli* transformed with pET28a–HSP60 vector were grown in LB medium (3 L) supplemented with kanamycin sulfate (50 μg/mL) in a shaking incubator at 180 rpm and 37°C until optical density at 600 nm reached 0.5. Next, 0.4 mM isopropyl-β-D-thiogalactopyranoside was added to the culture medium to induce the expression of the recombinant protein. After 6 hours, bacterial cells were harvested by centrifugation at 3,000 × g, were resuspended in a buffer (50 mM NaH₂PO₄, 300 mM NaCl, and 30 mM imidazole [pH 8.0]), and were lysed by sonication. Lipopolysaccharide and other bacterial contaminants were removed from the sample by washing it at least five times with a buffer containing 50 mM NaH₂PO₄, 300 mM NaCl, 2 M urea, 5 mM 2-mercaptoethanol, and 0.5% Triton X-100 (pH 8.0) through centrifugation at 10,000 × g [24]. Pellet containing the insoluble fraction (inclusions bodies) was resuspended in a denaturing solubilization buffer (50 mM NaH₂PO₄, 300 mM NaCl, 30 mM imidazole, 7 M urea, 5 mM 2-mercaptoethanol, and 0.5% Triton X-100 [pH 8.0]) and was incubated for 1 hour at room temperature. The denatured material was recovered by centrifugation at 10,000 × g and was filtered through Millex-GV PVDF (pore size, 0.22 μm; Millipore). The recombinant protein was purified by performing metal chelate affinity chromatography with a Ni²⁺–Sepharose affinity column (His-Trap; GE Healthcare). Next, the recombinant protein was eluted from the column with elution buffer (50 mM NaH₂PO₄, 300 mM NaCl, 250 mM imidazole, 7 M urea, and 5 mM 2-mercaptoethanol), refolded by dialysis against PBS, and concentrated by ultrafiltration. Protein concentration was determined using Coomassie Plus (Bradford) Assay Kit (Pierce Chemical Co.). Purity, size, and identity of the recombinant protein were evaluated using SDS-PAGE and 1D nLC-MS-MS, similar to those described above for column-eluted fraction. The rPbHsp60 preparation contained less than 0.05 ng/mL of bacterial endotoxin, as determined by the *Limulus* amoebocyte lysate assay (Sigma Chemical Co.).

Experimental Treatment Protocol

Mice were intravenously inoculated by retro-orbital plexus with 1 × 10⁶ viable yeast cells and daily monitored for signs of distress or illness, and mortality. None of them became seriously ill or died prior to the experimental endpoint. On day 21 postinfection, the mice were divided into groups containing five animals each. In experiments involving nPbHsp60, the mice were subcutaneously injected with a single 100 μL dose of one of the following preparations: (1) 25 μg nPbHsp60 in PBS, (2) 25 μg nPbHsp60 in PBS and emulsified in CFA (Sigma Chemical...
Co.) (nPbHsp60 + CFA, 1:1), (3) PBS emulsified in CFA, and (4) only PBS. In the experiments with recombinant protein, 50 μg of rPbHsp60 were used. On day 30 after the treatment, mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (8 mg/kg) mixture and submitted to euthanasia by cervical dislocation. Their lungs, livers, and spleens were removed aseptically for performing histopathological analyses and for quantifying fungal load and cytokine levels.

CFU, Tissue Injury and Cytokine Profile Evaluation
The right lungs and half portions of the livers and spleens were weighed and homogenized in 1 mL sterile PBS by using a tissue homogenizer (Ultra-Turrax T25 Basic; IKA Works, Inc., Wilmington, USA). Colony-forming units (CFU) of P. brasiliensis yeast cells were determined as described previously [23,25]. For determining cytokine levels, the organ homogenates were centrifuged at 5,000 × g for 10 minutes and their supernatants were stored at -20°C.

The left lungs and approximately half portions of the livers and spleens were fixed in 10% neutral buffered formalin for 24 hours and were embedded in paraffin. Next, the tissue sections (thickness, 5 μm) were stained with hematoxylin and eosin (H&E) by using standard protocols and were analyzed by performing light microscopy with Axiophot photomicroscope (Carl Zeiss, Jena, Germany) coupled with JVC TK-1270 camera (Victor Company of Japan Ltd, Tokyo, Japan). Total area of the lung sections and inflammatory infiltrates of P. brasiliensis yeasts per lung section were measured using a computer-aided image analysis software (ImageJ 1.37v; National Institutes of Health, Bethesda, USA).

Concentrations of IL-17, IFN-γ, TNF-α, IL-4, IL-10, IL-12, and TGF-β in the lung homogenates were measured by performing capture ELISA with OptEIA ELISA sets (BD PharMingen, San Diego, USA), according to the manufacturer’s protocol. Cytokine concentrations were determined by referring to a standard curve for serial two-fold dilutions of recombinant murine cytokines.

Statistical Analysis
Statistical differences among means of different experimental groups were determined using one-way analysis of variance followed by Bonferroni’s post-test. Differences were considered statistically significant at P < 0.05. All the experiments were performed at least three times.

Results
Isolation and Identification of 60 kDa Protein Isolated from PbAgs
A preparation of PbAgs was affinity chromatographed on an immobilized fetuin column. The bound proteins could not be eluted using carbohydrate solutions (0.4 M D-glucose, D-mannose, D-galactose, or α-lactose). Otherwise, protein elution was achieved by using 1 M NaCl solution in PBS, a fraction containing a 60-kDa major band on SDS-PAGE (Fig 1A) that comprised 68% of all proteins in the sample. The 60-kDa protein band was digested with trypsin and the one-dimensional nano-LC-MS/MS analysis of tryptic fragments revealed that 141 peptides matched the sequence of PbHsp60 (GenBank accession number: XP_010763632.1), resulting in a sequence coverage of 43% (S1 Fig and S1 Table). Because Hsp are protein highly conserved across the species, when we blasted the MS peptide sequences against the E. coli database, no correlation with E. coli GroEL or other proteins was found. Therefore, this enriched preparation of PbHsp60 was designed nPbHsp60, which was used, as indicated, in subsequent experiments.
Detrimental Effects of nPbHsp60 Administration to Mice with Experimental PCM

In initial experiments, we evaluated the effect of nPbHsp60 treatment on the course of experimental PCM in mice. Mice infected with *P. brasiliensis* yeast cells for 3 weeks were injected with nPbHsp60 or control preparations. The nPbHsp60-treated mice showed increased fungal load compared with PBS- or CFA-treated mice (Fig 1B). Treatment with CFA, an efficient inducer of Th1 response in *P. brasiliensis* infection [23], remarkably decreased the CFUs of *P. brasiliensis* yeasts in the lungs compared with treatment with PBS (Fig 1B).

Next, we determined whether the administration of nPbHsp60 changed the beneficial effects of CFA treatment. Intriguingly, when the *P. brasiliensis*-infected mice were treated with nPbHsp60 (25 μg) emulsified in CFA (nPbHsp60 + CFA), they had numbers of CFU on day 30 after treatment, at least, 2-fold higher than those detected in CFA-treated mice and quite similar to those in the lung from PBS-treated mice (infection control) (Fig 2A). These results indicate that the CFA effect in restraining fungal growth was decreased by nPbHsp60. Moreover, histological analysis showed an extensive lesion area (Fig 2B) with numerous granulomas containing high yeast load (Fig 2E) in the lungs of nPbHsp60 + CFA-treated and negative control mice (Fig 2C). In contrast, analysis of lung sections of *P. brasiliensis*-infected mice treated with CFA alone showed well-preserved bronchoalveolar architecture, with no detectable granulomas or yeast cells (Fig 2D). Moreover, no granulomas and yeast cells were detected in the livers and spleens of these mice. Together, these results supported the hypothesis that nPbHsp60 treatment impaired the beneficial effect of CFA against PCM.
To validate our presumption that PbHsp60 was responsible for the activities exerted by the fetuin-bound fraction, we expressed rPbHsp60 in pET-28a-HSP60-transformed E. coli cells and purified it by performing His-Trap chromatography. We analyzed the obtained protein by SDS-PAGE, which produced a single band with apparent molecular mass of 60-kDa. MS analysis confirmed that the recombinant protein was PbHsp60. No correlation with E. coli proteins was found when we blasted the MS peptide sequences against the E. coli database. This rPbHsp60 was biologically assayed by using the protocols adopted for experiments performed using nPbHsp60. At 51 days post-infection, i.e., 30 days after treatment of the P. brasiliensis-infected mice, we compared the fungal load and inflammation in the lungs, liver, and spleen of mice that received rPbHsp60 + CFA as treatment with those treated with CFA or PBS (Fig 3A–3C). As expected, CFA treatment decreased the fungal load compared with PBS, whereas rPbHsp60 + CFA duplicated the fungal load the examined organs, indicating that infection dissemination was lower in animals treated with CFA alone and maximum in mice injected with rPbHsp60 + CFA. Consistently, histopathological analysis showed that rPbHsp60 + CFA-injected mice had tissue injury more pronounced than CFA- or PBS-treated mice, an observation that was certified by the morphometric analysis of granulomatous lesions in the lung, liver, and spleen sections of the infected animals: the lesions occupied areas at least 50% more
Fig 3. Recombinant PbHsp60 disrupts the beneficial effect of CFA on experimental PCM. Mice inoculated with $1 \times 10^6 P. \text{brasiliensis}$ yeast cells were treated, on day 21 postinfection, with PBS, CFA, or CFA emulsified rPbHsp60 (rPbHsp60 + CFA; 50 μg). Thirty days after the treatment animals were sacrificed and lung (A), liver (B), and spleen (C) homogenates were analyzed for the CFU of $P. \text{brasiliensis}$ yeast cells. Data are expressed as the mean ± standard deviation of five mice per group obtained from three independent experiments. Sections (5-μm) of

---

Detrimental Effect of Fungal Hsp60 on Experimental Paracoccidioidomycosis
extended of the organs from rPbHsp60 + CFA-treated mice (Fig 3D–3F). Details of the pulmonary histology of the three groups of infected mice can be seen in Fig 3, Panels G-I. The comparative analysis of these panels shows that treatment with rPbHsp60 + CFA resulted in the formation of numerous loose granulomas with inflammation foci and dissemination of yeast cells in the lungs, whereas the CFA-treated mice displayed the most compact and well-structured granulomas (Fig 3H).

**rPbHsp60 Administration Increases the Production of Cytokines in the Lungs of *P. brasiliensis* Infected Mice**

We next investigated whether increased fungal load and pulmonary lesions in rPbHsp60 alone or rPbHsp60 + CFA-treated mice were associated with an unfavorable pattern of cytokine production in the lungs. Compared with CFA- or PBS-treated mice, the lungs of rPbHsp60 alone or rPbHsp60 + CFA-injected mice showed higher concentrations of different cytokines, including those of inflammatory (IL-17 and TNF-α), Th1 (IL-12 and IFN-γ), Th2 (IL-4), and regulatory (IL-10 and TGF-β) profiles (Fig 4). Notably, the most remarkable increase concerned the concentrations of proinflammatory cytokines IL-17, TNF-α, and IFN-γ, a condition that was consistent with severe inflammation and high fungal load observed in the lungs of rPbHsp60-treated mice (Fig 4).

**Discussion**

To find components of *P. brasiliensis* yeasts that might affect the outcome of PCM, we isolated an enriched fraction of PbHsp60, which had detrimental effects when administrated to *P. brasiliensis*-infected mice. The recombinant counterpart of PbHsp60 was prepared and administered to infected mice and reproduced the detrimental effects of the native preparation. In both cases, the treatment resulted in increased fungal load and disseminated disease, as well as in severe pulmonary inflammatory lesions. Furthermore, nPbHsp60 and rPbHsp60 antagonized the beneficial effects of CFA, a known inducer of Th1 immunity that confers protection against PCM [23]. Detection of high pulmonary concentrations of several cytokines, particularly inflammatory cytokines, suggested that aggravation of PCM resulted from a dysregulated immune response induced by rPbHsp60 administration.

Hsps are evolutionarily well-conserved proteins that function as molecular chaperones. Hsps play key roles in cellular homeostasis; participate in protein folding, unfolding, and assembly; and prevent protein aggregation and denaturation [26]. Although existing in basal conditions with their housekeeping functions in the cells, Hsps have their expression upregulated and are also fundamental to cell survival under stress, such as high temperatures, toxins, and oxidative conditions [27]. In dimorphic fungi, including *P. brasiliensis*, Hsps expression is increased during the conidia to yeast transition [28, 29], an event that may be important in the fungal pathogenesis when conidia reach the lungs of hosts [30]. In the characterization studies of Hsp60 from *P. brasiliensis*, the authors showed that this protein was overexpressed during morphological transition [31] and was recognized by sera from humans with PCM [31, 32]. Besides heat shock, host systems exert additional stress by inducing immune response to prevent fungal colonization and tissue invasion, suggesting that Hsps are required for promoting...
fungal survival within hosts. This also suggests that Hsps are one of the main targets of immune response [33].

Because fungal Hsp60s are immunodominant antigens that trigger strong cellular and humoral immune responses [27, 34, 35], they are interesting therapeutic and vaccinal targets [36]. Soares et al. [37] reported that rPbHsp60 may serve as an efficient vaccine component for treating experimental PCM. The differences between our results and those of Soares et al. [37] may be due to the different infection routes and protocols for the administration of recombinant PbHsp60. While Soares et al. [37] used intranasal infection, we performed intravenous infection, which mimics a disseminated form of the disease and advantageously constitutes a model for preclinical therapeutic trials [38]. Furthermore, we administrated rPbHsp60 in a therapy regimen, whereas Soares et al. [37] adopted a prophylactic regimen. The protocol used in the present study was designed on the basis of a previous study where treatment of *P. brasiliensis*-infected mice with CFA decreased fungal load in up to 2-log and substantially increased
the concentrations of protective cytokines [23]. In the present study, treatment of *P. brasiliensis*-infected mice with rPbHsp60 + CFA increased fungal load, number of diffuse granulomas with inflammation foci, and levels of all cytokines in lungs compared with that in *P. brasiliensis*-infected mice treated with CFA alone. Increased concentrations of proinflammatory cytokines (IL-17, TNF-α and IFN-γ) after rPbHsp60 treatment of *P. brasiliensis*-infected mice aggravated PCM, leading to severe inflammation, host tissue damage, impaired granuloma formation, and *P. brasiliensis* dissemination. Although anti-inflammatory cytokines IL-10 and TGF-β prevent inflammatory damage [39], lack of equilibrium in cytokine concentrations may favor tissue destruction. The risks of dysregulated cytokine production are clearly noted in other diseases, as septic shock syndrome [40, 41], which has a high mortality rate in humans [42]. Though anti-inflammatory cytokines are produced to compensate the high levels inflammatory response in patients with septic shock syndrome, they may be harmful, leading to cutaneous anergy, reduction of lymphocytes, decreased of monocytes response to cytokine stimulation, as well as decrease of human leukocytes antigens on monocytes [43]. Like in sepsis, an excessive cytokine production was harmful in *P. brasiliensis*-infected mice treated with PbHsp60, since that dysregulation may have been responsible, at the same time, for increased inflammation and tissue damage and decreased protective immune response against to *P. brasiliensis*, increasing the number of yeast in the tissue. Indeed, a fine-tuning between resistance and tolerance may explain the aspects of fungal infection, such as immunopathology and persistence [44].

Our study provides evidences that administered rPbHsp60 accounts for severe lesions in PCM and allows us to propose that PbHsp60 contributes to the fungal pathogenesis. Moreover, results of this study provide a perspective for controlling exacerbated immune responses and for designing new treatment approaches to induce appropriate immune response against deep mycosis.

**Supporting Information**

**S1 Fig.** MS/MS Mascot search data of the 60-kDa protein from *P. brasiliensis*. The 60-kDa band from *P. brasiliensis* was excised from the electrophoresis gel and digested *in situ* with trypsin. Peptides were extracted from gel and dried, resuspended in 50 μl 1% formic acid, centrifuged and transferred to HPLC vial. Spectrometry analyses were performed on an Agilent 6520 Q-TOF mass spectrometer equipped with an Agilent 1200 series liquid chromatograph and an Agilent Chip Cube LC-MS interface (1D nLC-MS-MS). Mascot (version 2.3; Matrix, United Kingdom) analysis was performed to identify peptides and to search for proteins in the NCBI nonredundant (nr) database.

(TIF)

**S1 Table.** List of all proteins matched with at least one peptide with a significant score.

(DOCX)

**Acknowledgments**

We thank Denise B. Ferraz, Patrícia E. Vendruscolo, Ana Flávia Gembre, and Vani Maria Alves for providing excellent technical assistance.

**Author Contributions**

Conceived and designed the experiments: FFF LLO APC.

Performed the experiments: FFF LLO TNL GP MVC.
Analyzed the data: FFF LLO MCRB APC.

Contributed reagents/materials/analysis tools: AAMCC VLDB MCRB APC.

Wrote the paper: FFF AAMCC VLDB MCRB APC.

References

1. Blotta MH, Mamoni RL, Oliveira SJ, Nourer SA, Papaioiordanou PM, Gouveia A, et al. Endemic regions of paracoccidioidomycosis in Brazil: a clinical and epidemiologic study of 584 cases in the southeast region. Am J Trop Med Hyg. 1999; 61(3):390–394. PMID: 10497977
2. Matute DR, McEwen JG, Puccia R, Montes BA, San-Blas B, Bagagi E, et al. Cryptic speciation and recombination in the fungus *Paracoccidioides brasiliensis* as revealed by gene genealogies. Mol Biol Evol. 2006; 23(1): 65–73. PMID: 16151188
3. Teixeira MM, Theodoro RC, de Carvalho MJ, Fernandes L, Paes HC, Hahn RC, et al. Phylogenetic analysis reveals a high level of speciation in the *Paracoccidioides* genus. Mol Phylogenet Evol. 2009; 52(2):273–283. doi: 10.1016/j.ympev.2009.04.005 PMID: 19376249
4. Kurokawa CS, Sugizaki MF, Peracoli MT. Virulence factors in fungi of systemic mycoses. Rev Inst Med Trop Sao Paulo. 1998; 40(3): 125–135. PMID: 9830725
5. Severo LC, Geyer GR, Londero AT, Porto NS, Rizzon CF. The primary pulmonary lymph node complex in paracoccidioidomycosis. Mycopathologia. 1979; 67(2): 115–118. PMID: 481558
6. Bethlem EP, Capone D, Maranhao B, Carvalho CR, Wanke B. Paracoccidioidomycosis. Curr Opin Pulm Med. 1999; 5(5): 319–325. PMID: 10461538
7. Martinez R. Epidemiology of Paracoccidioidomycosis. Rev Inst Med Trop Sao Paulo. 2015; 57 Suppl 19:11–20. doi: 10.1590/S0036-46652015000700004 PMID: 26465364
8. de Brito T, Franco MF. Granulomatous inflammation. Rev Inst Med Trop Sao Paulo. 1994; 36(2): 185–192. PMID: 7997797
9. San-Blas G, San-Blas F. *Paracoccidioides brasiliensis*: cell wall structure and virulence. A review. Mycopathologia. 1977; 62(2): 77–86. PMID: 340954
10. Coutinho ZF, Silva D, Lazera M, Petri V, Oliveira RM, Sabroza PC, et al. Paracoccidioidomycosis mortality in Brazil (1980–1995). Cad Saude Publica. 2002; 18(5): 1441–1454. PMID: 12244377
11. Robledo MA, Graybill JR, Ahrens J, Restrepo A, Drutz DJ, Robledo M. Host defense against experimental paracoccidioidomycosis. Am Rev Respir Dis. 1982; 125(5): 563–567. PMID: 7091817
12. McInturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol. 2005; 125(1): 1–8. PMID: 15962906
13. Bonfim CV, Mamoni RL, Blotta MH. TLR-2, TLR-4 and dectin-1 expression in human monocytes and neutrophils stimulated by *Paracoccidioides brasiliensis*. Med Mycol. 2009; 47(7): 722–733. doi: 10.3109/13693780802641425 PMID: 19888805
14. Lopes JD, Moura-Campos MC, Vicentini AP, Gesztesi JL, de Souza W, Camargo ZP. Characterization of glycoprotein gp43, the major laminin-binding protein of *Paracoccidioides brasiliensis*. Braz J Med Biol Res. 1994; 27(9): 2309–2313. PMID: 7787814
15. Vicentini AP, Gesztesi JL, Franco MF, de Souza W, de Moraes JZ, Travassos LR, et al. Binding of *Paracoccidioides brasiliensis* to laminin through surface glycoprotein gp43 leads to enhancement of fungal pathogenesis. Infect Immun. 1994; 62(4): 1465–1469. PMID: 8132354
16. Ribeiro AM, Bocca AL, Amaral AC, Souza AC, Faccioli LH, Coelho-Castelo AA, et al. HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis. Vaccine. 2010; 28(6): 1528–1534. doi: 10.1016/j.vaccine.2009.11.062 PMID: 20045500
17. Rittner GM, Munoz JE, Marques AF, Nosanchuk JD, Taborda CP, Travassos LR. Therapeutic DNA vaccine encoding peptide P10 against experimental paracoccidioidomycosis. PLoS Negl Trop Dis. 2012; 6(2): e1519. doi: 10.1371/journal.pntd.0001519 PMID: 22387934
18. Reis BS, Fernandes VC, Martins EM, Serakides R, Goes AM. Protective immunity induced by rPb27 of *Paracoccidioides brasiliensis*. Vaccine. 2008; 26(43): 5461–5469. doi: 10.1016/j.vaccine.2008.07.097 PMID: 18722494
19. Fernandes VC, Martins EM, Boeloni JN, Coitinho JB, Serakides R, Goes AM. Additive effect of rPb27 immunization and chemotherapy in experimental paracoccidioidomycosis. PLoS One. 2011; 6(3): e17865. doi: 10.1371/journal.pone.0017865 PMID: 21423771
20. Fernandes VC, Martins EM, Boeloni JN, Coitinho JB, Serakides R, Goes AM. The combined use of *Paracoccidioides brasiliensis* Pb40 and Pb27 recombinant proteins enhances chemotherapy effects in...
experimental paracoccidioidomycosis. Microbes Infect. 2011; 13(12–13): 1062–1072. doi: 10.1016/j.micinf.2011.06.004 PMID: 21726659

21. Alegre-Maller AC, Mendonca FC, da Silva TA, Oliveira AF, Freitas MS, Hanna ES, et al. Therapeutic administration of recombinant Paracoccin confers protection against Paracoccidioides brasiliensis infection: involvement of TLRs. PLoS Negl Trop Dis. 2014; 8(12): e3317. doi: 10.1371/journal.pntd.0003317 PMID: 25474158

22. Calich VL, Purchio A, Paula CR. A new fluorescent viability test for fungi cells. Mycopathologia. 1979; 66(3): 175–177. PMID: 375098

23. de Oliveira LL, Coltri KC, Cardoso CR, Roque-Barreira MC, Panunto-Castelo A. T helper 1-inducing adjuvant protects against experimental paracoccidioidomycosis. PLoS Negl Trop Dis. 2008; 2(3): e183. doi: 10.1371/journal.pntd.0000183 PMID: 18335066

24. Alekseeva MG, Mavletova DA, Kolchina NV, Nezametdinova VZ, Danilenko VN. Isolation and purification of recombinant serine/threonine protein kinases of the strain Bifidobacterium longum B379M and investigation of their activity. Biochemistry (Mosc). 2015; 80(10): 1303–1311.

25. Peracoli MT, Kurokawa CS, Calvi SA, Mendes RP, Pereira PC, Marques SA, et al. Production of pro-and anti-inflammatory cytokines by monocytes from patients with paracoccidioidomycosis. Microbes Infect. 2003; 5(5): 413–418. PMID: 12737997

26. Vabulas RM, Raychaudhuri S, Hayer-Hartl M, Hartl FU. Protein folding in the cytoplasm and the heat shock response. Cold Spring Harb Perspect Biol. 2010; 2(12): a004390. doi: 10.1101/cshperspect.a004390 PMID: 21123396

27. Falkowska-Podstawka M, Wernicki A. Heat shock proteins in health and disease. Pol J Vet Sci. 2003; 6(5): 462

28. Hernandez O, Garcia AM, Almeida AJ, Tamayo D, Gonzalez A, Restrepo A, et al. Gene expression during activation of Paracoccidioides brasiliensis conidia. Yeast. 2011; 28(11): 771–781. doi: 10.1002/yea.1902 PMID: 21960298

29. Nicola AM, Andrade RV, Dantas AS, Andrade PA, Arraes FB, Fernandes L, et al. The stress responsive and morphologically regulated hsp90 gene from Paracoccidioides brasiliensis is essential to cell viability. BMC Microbiol. 2008; 8: 158. doi: 10.1186/1471-2180-8-158 PMID: 18808717

30. Restrepo A, Cano LE, Gonzalez A. The power of the small: the example of Paracoccidioides brasiliensis conidia. Rev Inst Med Trop Sao Paulo. 2015; 57 Suppl 19: 5

31. Izacc SM, Gomez FJ, Jesuino RS, Fonseca CA, Felipe MS, Deepe GS, et al. Molecular cloning, characterization and expression of the heat shock protein 60 gene from the human pathogenic fungus Paracoccidioides brasiliensis. Med Mycol. 2001; 39(5): 445–455. PMID: 12054056

32. Cunha DA, Zancope-Oliveira RM, Sueli M, Felipe S, Salem-Izacc SM, Deepe GS Jr., et al. Heterologous expression, purification, and immunological reactivity of a recombinant HSP60 from Paracoccidioides brasiliensis. Clin Diagn Lab Immunol. 2002; 9(2): 374–377. PMID: 11874881

33. Kaufmann SH. Heat shock proteins and the immune response. Immunol Today. 1990; 11(4): 129–136. PMID: 2187470

34. Moingeon P, Almond J, de Wilde M. Therapeutic vaccines against infectious diseases. Curr Opin Microbiol. 2003; 6(5): 462–471. PMID: 14572538

35. Zugel U, Kaufmann SH. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev. 1999; 12(1): 19–39. PMID: 9880473

36. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines. 2008; 7(8): 1185–1199. doi: 10.1586/14760584.7.8.1185 PMID: 18845533

37. Soares RBA, Gomez FJ, de Almeida Soares CM, Deepe GS Jr., Vaccination with heat shock protein 60 induces a protective immune response against experimental Paracoccidioides brasiliensis pulmonary infection. Infect Immun. 2008; 76(9): 4214–4221. doi: 10.1128/IAI.00753-07 PMID: 18625731

38. Ueda AK, Franco M, Fabio SA, Prestes FR. Ketoconazole in the treatment of experimental murine paracoccidioidomycosis. Mycopathologia. 1987; 98(1): 27–34. PMID: 3587333

39. Kurokawa CS, Araujo JP Jr., Soares AM, Sugizaki MF, Peracoli MT. Pro- and anti-inflammatory cytokines produced by human monocytes challenged in vitro with Paracoccidioides brasiliensis. Microbiol Immunol. 2007; 51(4): 412–418. PMID: 17446881

40. Cohen J. The immunopathogenesis of sepsis. Nature. 2002; 420(6917): 885–891. PMID: 12490963

41. Junger WG, Hoyt DB, Liu FC, Loomis WH, Coimbra R. Immunosuppression after endotoxin shock: the result of multiple anti-inflammatory factors. J Trauma. 1996; 40(5): 702–709. PMID: 8614067
42. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007; 35(5): 1244–1250. PMID: 17414736

43. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008; 29(4): 617–625, viii.

44. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011; 11(4): 275–288. doi: 10.1038/nri2939 PMID: 21394104